{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-152145","form_type":"8-K","ticker":"RPRX","cik":"0001802768","company_name":"Royalty Pharma plc","filed_at":"2026-04-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.935236+00:00","generated_at":"2026-05-15T06:36:06.838556+00:00","sec_items":["7.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Royalty Pharma triggers $250M milestone after positive daraxonrasib Phase 3 results","bullets":["Revolution Medicines' RASolute 302 trial met primary and key secondary endpoints (PFS and OS) in metastatic PDAC.","Royalty Pharma funded $250M upfront; positive data triggers additional $250M milestone, total $500M funded.","Royalty Pharma now earns 4.55% tiered royalty on daraxonrasib sales up to $2B, lower rates above $2B.","Additional $750M synthetic royalty available upon FDA approval and other milestones; first $250M on approval.","Senior secured loan of up to $750M available; first $250M tranche must be drawn after FDA approval."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-152145","json":"https://secwatch.observer/filing/0001193125-26-152145.json","markdown":"https://secwatch.observer/filing/0001193125-26-152145.md","text":"https://secwatch.observer/filing/0001193125-26-152145.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1802768/000119312526152145/0001193125-26-152145-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1802768/000119312526152145/d871473d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T06:36:06.838556+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}